Product image of Micofenolato Mofetile Tillomed Italia (Mycophenolate Mofetil) supplied by GNH India

Micofenolato Mofetile Tillomed Italia

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Micofenolato Mofetile Tillomed Italia (Mycophenolate Mofetil)

Mycophenolate mofetil, the active ingredient in Micofenolato Mofetile Tillomed Italia, is an antimetabolite presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis by suppressing immune activity.

GNH India supplies Micofenolato Mofetile Tillomed Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Tillomed Italia S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mycophenolate mofetil is an immunosuppressant that acts on T‑ and B‑lymphocyte proliferation in several transplant‑related and autoimmune conditions.

  • Organ transplant rejection: helps prevent acute rejection after kidney, heart or liver transplantation.
  • Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus.
  • Graft‑versus‑host disease prophylaxis: lowers the incidence of GVHD following hematopoietic stem cell transplantation.

How It Works

  • Mycophenolate mofetil is converted in vivo to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase. This blocks de novo guanosine nucleotide synthesis, a pathway essential for the proliferation of activated T and B lymphocytes, thereby dampening cellular and humoral immune responses.

Side Effects

Mycophenolate mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools that may require hydration.
  • Headache: transient cranial discomfort.
  • Tremor: fine shaking of hands or limbs.
  • Abdominal pain: crampy discomfort in the stomach area.

Serious or Rare Side Effects

  • Severe infection: opportunistic infections due to immune suppression.
  • Leukopenia: marked reduction in white blood cells.
  • Anemia: decreased red blood cell count leading to fatigue.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Malignancy risk: increased incidence of certain cancers with long‑term use.

Precautions & Warnings

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors.

  • Monitor blood counts: perform regular CBC to detect leukopenia or anemia.
  • Assess renal function: adjust therapy if creatinine clearance is reduced.
  • Contraindicated in pregnancy: avoid use due to teratogenic risk (Category X).
  • Avoid live vaccines: immunosuppression may permit uncontrolled infection.
  • Review concomitant nephrotoxic drugs: limit combined exposure to protect kidneys.
  • Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Avoid Interactions

Mycophenolate mofetil can interact with several agents, altering efficacy or safety.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression may cause severe cytopenias.
  • Ribavirin: combined immunosuppression increases infection risk.
  • Live vaccines: heightened risk of vaccine‑derived disease.

Moderate Interactions (Monitor Closely)

  • Cyclosporine: may raise mycophenolate plasma levels, requiring dose adjustment.
  • Tacrolimus: similar effect on mycophenolate exposure.
  • Antacids containing aluminum or magnesium: can reduce mycophenolate absorption; separate administration by at least 2 hours.

Frequently Asked Questions

Micofenolato Mofetile contains mycophenolate mofetil, which is prescribed to prevent acute rejection after organ transplantation and to treat lupus nephritis. It is also used as prophylaxis against graft‑versus‑host disease in hematopoietic stem cell transplant patients.

After oral administration, mycophenolate mofetil is converted to mycophenolic acid, which blocks inosine monophosphate dehydrogenase. This inhibition stops the synthesis of guanosine nucleotides, a critical step for the proliferation of activated T and B lymphocytes, thereby suppressing the immune response.

The specific dose of Micofenolato Mofetile is determined by the prescribing physician based on the patient’s condition, weight, renal function and other clinical factors. The prescriber will set the appropriate regimen and any necessary adjustments.

Mycophenolate mofetil is classified as Pregnancy Category X because it is known to cause fetal malformations and embryotoxicity. It should not be used by pregnant women, and effective contraception is required during treatment and for several weeks after discontinuation. Breastfeeding is also contraindicated.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination with other agents to achieve synergistic immunosuppression while allowing lower doses of each drug, potentially reducing individual side‑effect profiles.

Micofenolato Mofetile should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

The most serious risks include severe infections due to immune suppression, bone‑marrow suppression leading to leukopenia or anemia, and potential liver toxicity. Patients should be monitored regularly for signs of infection, blood‑cell abnormalities and hepatic dysfunction.

Micofenolato Mofetile is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate mofetil or its excipients, and patients with severe, uncontrolled infections. Caution is also advised for those with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT